# The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD

> **NCT06542445** · PHASE2 · RECRUITING · sponsor: **Bazelet Nehushtan LtD.** · enrollment: 120 (estimated)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** Oral CBD oil enriched with terpenes
- **DRUG:** Oral Placebo

## Key facts

- **NCT ID:** NCT06542445
- **Lead sponsor:** Bazelet Nehushtan LtD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2026-08-22
- **Final completion:** 2026-09-22
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06542445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06542445, "The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06542445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*